Gratitude
Drugs don’t work if people can’t afford them.
JOIN THE FIGHT TO LOWER DRUG PRICES

Email address
Our Theory of Change:
Reform is more likely with an independent patient voice
OUR WORK

• Amplify the patient voice
• Educate, activate and mobilize patients
Solutions

- Medicare negotiations
- PBM transparency
- Speed generics to market
- Justify price when drug developed with taxpayer funding
- Price for new drugs based on value to patients
Nevada just passed one of the strictest drug pricing transparency laws in the country.

Maryland General Assembly passes bill aimed at drug 'price gouging'.

California Assembly passes drug price transparency bill.
FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag

Pioneering Cancer Gene Therapy Gets Green Light – And $475,000 Price Tag

Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
What do we want?

• Fair & transparent pricing in light of taxpayer investment
• U.S. patients pay no more than other wealthy countries
• Lower prices as patient population increases
Why do we think Kymriah priced too high?

2012 – Dr. June put price of goods at $20,000
2015 – Kite CFO says price should be about $150,000
2017 – Novartis CEO claims company spent $1 billion before ODA credit
2017 – U.S. plant and equipment $43 million
2017 – NICE study willing to pay $460,000, not $650,000 price as popularly reported
On top of the economic facts, there is this:

Kymriah “is grounded in initial basic research supported by NIH. With immunotherapy, as with so many of our medical interventions, the path from original discovery or observation to effective treatment is long, circuitous, and densely populated. Immunotherapy is indeed the achievement of many minds.”

--NIH Director Francis Collins, August 29, 2017
What do we think Kymriah should cost?

Based on all the data points and our own modeling, we think it is priced about $125,000-150,000 too high.
Where to from here on CAR-T?

• Educate patients and policymakers
• Continue to work for recognition of taxpayer funding early and ODA credits later
• Continue to urge restraint from Novartis
• Reach out to Gilead and Juno to encourage responsible pricing
Contact and Resources:

David@patientsforaffordabledrugs.org

@DavidP4AD

Patients For Affordable Drugs